[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406538-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406538-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","systemic-treatments-in-pancreatic-cancer-taiwan-pancreas-society-recommendation","Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation","","Pancreatic cancer is a highly aggressive malignancy with a poor prognosis, despite progress over the past decade. Therapeutic advances, particularly chemotherapy evolution from single agents to doublet or triplet regimens and the use of multimodal strategies, have improved survival. Targeted agents for specific genetic alterations and emerging cell therapies may benefit selected subpopulations. This review synthesizes key studies across neoadjuvant, adjuvant, maintenance, and salvage settings and summarizes ongoing metastatic trials, with added Taiwan clinical trial and real-world perspectives to support evidence-based recommendations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/systemic-treatments-in-pancreatic-cancer-taiwan-pancreas-society-recommendation/406538/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/systemic-treatments-in-pancreatic-cancer-taiwan-pancreas-society-recommendation/406538.png","ImageObject",300,407,{"name":42,"@type":43},"A glass of water","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the review focus on regarding systemic treatments for pancreatic cancer?","Question",{"text":63,"@type":64},"It examines pivotal studies on chemotherapy roles in neoadjuvant, adjuvant, maintenance, and salvage settings, highlights findings related to cell therapy, and provides an overview of ongoing trials in metastatic disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How have chemotherapy strategies changed over the past decade according to the abstract?",{"text":68,"@type":64},"The review attributes improved outcomes to chemotherapy evolution from monotherapy to doublet or triplet regimens and integration of multimodal approaches.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is there interest in targeted agents and cell therapies?",{"text":72,"@type":64},"Targeted agents tailored to specific genetic alterations and the development of cell therapies are described as promising for certain patient subpopulations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406538,1790971311,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},962090760832,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Biomedical Journal 47 (2024) 100696  \nContents lists available at ScienceDirect Biomedical Journal  \njournal [homepage:](homepage: www.elsevier.com/locate/bj)[ www.elsevier.com/locate/bj](homepage: www.elsevier.com/locate/bj)  \n| Review Article\u003Cbr>Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation |  |  | |\n| --- | --- | --- | --- |\n| Yung-Yeh Sua, b, c, 1, Nai-Jung Chiang a, d, e, f, 1, Tai-Jan Chiug, h, Chien-Jui Huang i,\u003Cbr>Shao-Jung Hsue, f,j, Hsin-Chen Link, Shih-Hung Yang l, Youngsen Yang m, n, Wen-Chi Chou h, o, Yen-Yang Chen g, h, Li-Yuan Bain, p, Chung-Pin Li e, f,j, q, 2, *, Jen-Shi Chenh, o, 2, **\u003Cbr>a National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan\u003Cbr>b Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan\u003Cbr>c Department of Internal Medicine, Kaohsiung Medical University Hospital, and Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan d Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan\u003Cbr>e School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan\u003Cbr>f Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan\u003Cbr>g Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan h Chang Gung University College of Medicine, Taoyuan, Taiwan\u003Cbr>i Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan\u003Cbr>j Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan k Division of Medical Oncology, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan l Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan\u003Cbr>m Division of Cancer Prevention and Control, Department of Oncology, Taichung Veterans General Hospital, Taichung, Taiwan n College of Medicine, School of Medicine, China Medical University, Taichung, Taiwan\u003Cbr>o Department of Hematology-Oncology, Linkou Chang Gung Memorial Hospital, Taiwan\u003Cbr>p Division of Hematology and Oncology, China Medical University Hospital, China Medical University, Taichung, Taiwan q Division of Clinical Skills Training, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: Pancreatic cancer Chemotherapy\u003Cbr>Postoperative adjuvant chemotherapy Neoadjuvant therapy |  | Pancreatic cancer is a highly aggressive malignancy with a poor prognosis. Over the past decade, significant therapeutic advancements have improved the survival rates of patients with pancreatic cancer. One of the primary factors contributing to these positive outcomes is the evolution of chemotherapy, from monotherapy to doublet or triplet regimens, and the integration of multimodal approaches. Additionally, targeted agents tailored to patients with specific genetic alterations and the development of cell therapies show promise in benefiting certain subpopulations. This article focuses on examining pivotal studies that explore the role of chemotherapy in neoadjuvant, adjuvant, maintenance, and salvage settings; highlights interesting findings related to cell therapy; and provides an overview of ongoing trials concerning metastatic settings. This review primarily aimed to offer recommendations based on therapeutic evidence, recent advancements in new treatment combinations, and the most innovative approaches. A unique aspect of this review is the inclusion of published papers on clinical trials and real-world data in Taiwan, thus adding a valuable perspective to the overall analysis. |  |\n\nPeer review under responsibility of Chang Gung University.  \n* Corresponding author. Divisio","cbCaimBh0A2rK4kr","https://ap.wps.com/l/cbCaimBh0A2rK4kr","pdf",599132,"English","# Introduction\n# Systemic therapy overview\n## Neoadjuvant, adjuvant, maintenance, and salvage settings\n## Chemotherapy regimens and targeted approaches\n## Cell therapy and ongoing metastatic trials","[{\"question\":\"What does the review focus on regarding systemic treatments for pancreatic cancer?\",\"answer\":\"It examines pivotal studies on chemotherapy roles in neoadjuvant, adjuvant, maintenance, and salvage settings, highlights findings related to cell therapy, and provides an overview of ongoing trials in metastatic disease.\"},{\"question\":\"How have chemotherapy strategies changed over the past decade according to the abstract?\",\"answer\":\"The review attributes improved outcomes to chemotherapy evolution from monotherapy to doublet or triplet regimens and integration of multimodal approaches.\"},{\"question\":\"Why is there interest in targeted agents and cell therapies?\",\"answer\":\"Targeted agents tailored to specific genetic alterations and the development of cell therapies are described as promising for certain patient subpopulations.\"}]","Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation | PDF",1790566296,25]